Portola Valley · Pre-Seed–Late Stage · 31 people tracked
Also known as LSV CAPITAL MANAGEMENT, LLC
Investment thesis
Lightstone Ventures pursues a thesis-driven life sciences strategy focused on biotech and medtech. In biotech it seeks first-in-class drugs across all modalities including small molecules, biologics, and cell and gene therapies, with emphasis on CNS, immunology and autoimmune diseases, oncology, and ophthalmology. In medtech it targets the convergence of technology, medicine, and consumer health, including personalized medicines, targeted therapeutics leveraging data analytics, and medical technologies addressing immunology, cardiovascular, neurology, and ophthalmology. The firm invests with long-term, patient capital funding companies from startup through commercialization, and partners hands-on with founders on strategy and company building rather than simply providing capital.
Source: firm website, verified Aug 25, 2026.
Team · 31 people
from the firm's website & curated & public directories
Founder mafia
3 people who came through Lightstone Ventures went on to found or lead other companies.
+ 1 more
What they invest in
from 58 of 83 portfolio companiesHealthtech ×40Biotech ×34Medical Devices ×30Deep Tech ×8Hardware ×7AI & Machine Learning ×5Digital Health ×5Advanced Manufacturing ×1
HQs:United States×38Ireland×2Canada×1United Kingdom×1Netherlands×1Singapore×1
Who they back
founder profiles across 8 portfolio companiesFounding team size:solo founder×42 founders×23 founders×14+ founders×1
Investments · 83 tracked
founders shown can be your intro pathBy year:2026 · 12025 · 32023 · 32019 · 42018 · 12016 · 42015 · 62014 · 426 dated
Shoulder Innovations develops InSet® glenoid technology for shoulder joint implants that reduce the rocking horse effect and provide mechanical stability, serving patients with severe shoulder arthritis.
HardwareHealthtechMedical DevicesNorthern California, US
Robert Ball(CEO & Executive Chairman)Matthew Ahearn(Chief Operating Officer)Jeff Points(Executive Officer)David Blue(Executive Officer)Don Running(Manager and Chief Executive Officer)Jeff Ondrla(Chief Technology Officer)
Board seatMike Carusi· per SEC Form D
Co-investorsAPERTURE Venture PartnersArboretum VenturesGenesis Innovation GroupGlobal BrainInvest MichiganUS Venture Partners+2 more
ALX Oncology is a clinical-stage biopharmaceutical company developing cancer therapies, including its lead candidate evorpacept for immuno-oncology and ALX2004, an antibody-drug conjugate targeting EGFR-positive tumors.
BiotechHealthtech
Co-investorsage1Foresite CapitalvenBio Partners
Verastem Oncology is a biopharmaceutical company that discovers and develops drugs to treat cancer patients.
BiotechMedical DevicesNeedham, US
Robert WeinbergRICHARD ALDRICH(Director)AMY C. CAVERS(Executive Officer)CATHY CAREW(Executive Officer)JONATHAN PACHTER(Executive Officer)ROB GAGNON(Executive Officer)
Co-investorsBessemer Venture PartnersCardinal PartnersForesite CapitalLongwood FundOberland CapitalOrbiMed
Contego Medical develops the Neuroguard IEP System, a 3-in-1 carotid stenting device combining a carotid stent, dilation balloon, and integrated embolic protection with a 40-micron filter to reduce stroke and cognitive impairment from microembolization.
HardwareHealthtechMedical DevicesRaleigh, US
Ravish Sachar(CEO & Founder)Paul Sanders(Chief Operating Officer)
Board seatHanson S. Gifford· per SEC Form D
Co-investorsHatteras Venture PartnersAmzak HealthMountain Group CapitalUS Venture Partners
PsiThera is a biotechnology company using computational and physics-based methods—including quantum mechanics, molecular dynamics, machine learning, and simulation—for mechanism-driven drug design and discovery.
AI & Machine LearningBiotechDeep Tech
Co-investorsSamsara BioCapital
Vesper Medical develops a modular venous stent portfolio designed to address the anatomical challenges of the iliac and femoral veins for treating deep venous disease.
HealthtechMedical DevicesWayne, US
Bruce J. Shook(President and CEO)Monica Klos(Executive Officer)Neil Hattangadi(Director)Peter Schneider(Director)Mark Garcia(Director)Dennis W. Wahr(Director)
Co-investorsNew Enterprise Associates (NEA)Gilde HealthcareVensana Capital415 Capital
Allay Therapeutics develops localized pain management technology designed to deliver several weeks of post-surgical pain relief.
BiotechHealthtechMedical DevicesSan Jose, US
Adam Gridley(Executive Officer, Director)Kristen Howells(Executive Officer)Josh Makower(Director)Tak Cheung(Director)Karun D. Naga(Executive Officer, Director)
BoardLeighton Read(Director)
Board seatMichael A. CarusiHanson S. Gifford· per SEC Form D
Co-investorsArboretum VenturesNew Enterprise Associates (NEA)SGInnovateClavystBio
Apreo Health develops a bronchoscopic treatment for severe emphysema using a self-expanding airway scaffold designed to reduce trapped air and improve lung function.
BiotechHealthtechMedical DevicesMenlo Park, US
Karun Durgam Naga(Executive Officer, Director)
BoardHanson S. Gifford III(Director)Zack Scott(Director)Drew Field(Director)Dennis McWilliams(Director)
Board seatHanson S. GiffordMichael A. Carusi· per SEC Form D
Co-investorsF-Prime CapitalIntuitive VenturesNorwest Venture Partners
BiotechSouth San Fransicso, US
Nassim Usman(Executive Officer, Director)
BoardAugustine Lawlor(Director)Ralph Christoffersen(Director)inJeff Himawan(Director)Michael Powell(Director)Asish Xavier(Director)
Board seatRalph (Chris) Christoffersen· per SEC Form D · $5M raise · filed Feb 2015
Co-investorsResearch Corporation Technologies
FemTechHealthtechMedical DevicesRedwood City, US
Christopher Owens(Executive Officer, Director)Darrin Uecker(Executive Officer, Director)
BoardKen Haas(Director)Jonathan MacQuitty(Director)inDoug Fisher(Director)
Board seatMike Carusi· per SEC Form D
Co-investorsAmzak HealthBain Capital Life SciencesEndeavour VisionFemHealth VenturesKaiser Permanente VenturesKluz Ventures+5 more
HealthtechMenlo Park, US
BoardMark Deem(Director)inHanson S. Gifford, III(Executive Officer, Director)
Board seatHanson S. Gifford· per SEC Form D · $1M raise · filed Feb 2023
Imperative Care develops medical technologies for treating stroke and other vascular diseases, aiming to address gaps across the patient care journey.
HealthtechMedical DevicesCampbell, US
Farhad Khosravi(Executive Officer, Director)Matthew Garrett(Executive Officer)Charles Alpuche(Executive Officer)Scott Elliott(Executive Officer)
BoardJames Rogers(Director)Stacy Enxing Seng(Director)
Board seatHenry Albert Plain, Jr.· per SEC Form D · $100M raise · filed Mar 2026
Co-investorsAscension VenturesDelos CapitalFemHealth Ventures
BiotechBellevue, US
Michael Gertner(Executive Officer, Director)
BoardLouis Cannon(Director)Christopher Shen(Director)Immanuel Thangaraj(Director)Brian Halak(Director)in
Board seatHenry A. Plain, Jr.· per SEC Form D · $22.4M raise · filed Sep 2015
Co-investorsDomain Associates
Singapore-based immune engineering company developing novel cellular therapies for T-cell malignancies and autoimmune diseases.
Singapore
Board seatMichael A. Carusi· per SEC Form D
Co-investorsClavystBioOUP (Osage University Partners)
HealthtechSanta Clara, US
R. Michael Kleine(Executive Officer, Director)Brigid Makes(Executive Officer)Steven Kim(Executive Officer)Henry A. Plain, Jr.(Director)
BoardHanson Gifford III(Director)Henry Plain, Jr.(Director)
Board seatHanson S. Gifford· per SEC Form D · $33.6M raise · filed Jun 2016
Co-investorsDomain Partners
Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD).
HardwareHealthtechMedical DevicesMinneapolis, US
Martin Mayse(Co-founder)Steve Dimmer(Co-founder)Dennis Wahr(President & CEO)Lisa Flaherty(Chief Strategy Officer)Steve Sathre(Vice President of Finance)Steve Paidosh(Vice President of Operations)
Board seatMichael A, CarusiHenry PlainMichael A. CarusiMike CarusiHank Plain· per SEC Form D · $17.3M raise · filed Dec 2023
Co-investorsWindham Capital PartnersQiming Venture Partners
HealthtechBelmont, US
S. Arieh Zak(Executive Officer)Barry Cheskin(Executive Officer, Director)Drew Schiff(Director)Michael Carusi(Director)Lou Bock(Director)George Green(Executive Officer)
Board seatMichael Carusi· per SEC Form D
Co-investorsAisling CapitalArcher Capital GroupArcher Venture Capital
Reprieve Cardiovascular develops a decongestion management system that uses real-time patient data to guide and personalize diuretic therapy for fluid removal in heart failure patients.
Digital HealthHealthtechMedical DevicesMilford, US
Tony Fields(Executive Officer)Adam Bartnik(Executive Officer)Mark Pacyna(Executive Officer, Director)inJim Dillon(Executive Officer, Director)Hanson S. Gifford III(Director)Gregory W Mann(Executive Officer)
Board seatHanson S. Gifford· per SEC Form D
Co-investorsArboretum VenturesRex Health VenturesDeerfield Management CompanyGenesis Venture CapitalSante Ventures
Tangible Science develops contact lens solutions designed to improve comfort and durability for wearers and to provide eye care professionals with more effective treatment options.
HealthtechMedical DevicesMenlo Park, US
Karen Havenstrite(Director)Victor McCray(Executive Officer, Director)
BoardDouglas Crawford(Director)inHanson Gifford(Director)Chip Heath(Director)Brandon Felkins(Director)
Board seatHanson S. Gifford· per SEC Form D · $4.6M raise · filed Nov 2016
Co-investorsMission Biocapital
Twelve transforms CO2 into chemicals, fuels, and materials through carbon transformation technology.
Advanced ManufacturingCleantechClimate TechHealthtechNew MaterialsMoses Lake, US
Nicholas Flanders(Founder & CEO)inEtosha Cave(Founder)inKendra Kuhl(Founder)inAndrew Cleeland(Executive Officer, Director)
BoardMarc-Henri Galletti(Director)Nimesh Shah(Director)
Board seatHanson S. GiffordHenry A. Plain, Jr.· per SEC Form D
Co-investorsBreakout VenturesDCVC (Data Collective)Dolby Family VenturesFifth WallAdvantage Partners Inc.Aera VC+15 more
A drug discovery and therapeutic company creation platform that accelerates the development of new medicines from research institutions in Singapore.
BiotechDeep TechSingapore, SG
Co-investorsClavystBioLeaps by Bayer
A pharmaceutical company that develops medicines and vaccines for patients globally.
BiotechHealthtechMedical DevicesCambridge, US
WYLIE W. VALE(Director)JOHN KNOPF(Executive Officer, Director)STEVEN ERTEL(Executive Officer)ROBERT STEININGER(Executive Officer)KEVIN F. MCLAUGHLIN(Executive Officer)MATTHEW L. SHERMAN(Executive Officer)
Co-investorsBessemer Venture PartnersForesite CapitalLowercarbon CapitalSofinnova VenturesVenrockCollaborative Fund
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Co-investorsSV Health InvestorsDCVC BioRA CapitalDementia Discovery FundOno Venture Investment, Inc.DCVC (Data Collective)
Amber Therapeutics develops medical technology focused on treating mixed urinary incontinence, advancing toward pivotal clinical trials in the US with expanded feasibility studies in Europe.
Medical Devices
Co-investorsF-Prime CapitalIntuitive VenturesNew Enterprise Associates (NEA)Oxford Science Enterprises
Co-investorsHatteras Venture PartnersOUP (Osage University Partners)
Atsena Therapeutics is a clinical-stage gene therapy company developing treatments for inherited retinal diseases.
BiotechMedical Devices
Co-investorsHatteras Venture PartnersSofinnova Ventures
Bonito develops encoded library and live-cell selection technologies to discover delivery ligands, generating high signal-to-noise data on membrane-bound targets to train AI models for precision drug delivery.
AI & Machine LearningBiotechDeep Tech
Richard Wagner(CEO, Cofounder)
Co-investorsJAZZ Venture Partners
Cala Health develops non-invasive prescription therapies for movement disorders, starting with a treatment for hand tremor and essential tremor.
Deep TechDigital HealthHealthtechMedical DevicesSilicon Valley, US
Kate Rosenbluth, PhD(President & Chief Innovation Officer)Kate Rosenbluth(Founder)inDeanna Harshbarger(Chief Executive Officer)
Co-investorsAscension VenturesGlobal BrainGV (Google Ventures)OSF VenturesTriventuresAME Cloud Ventures+1 more
CardiacBooster is a medical device company developing a high-flow, low-profile percutaneous ventricular assist device (pVAD) for temporary cardiac support in patients with cardiogenic shock and those undergoing high-risk coronary procedures (high-risk PCI).
HardwareHealthtechMedical DevicesGalway, IE
Co-investorsAscension Ventures
Carrick Therapeutics is a biopharmaceutical company with a leadership team experienced in oncology drug development and commercialization.
BiotechDigital HealthHealthtechMedical Devices
Timothy Pearson(CEO)Ash Bahl(CSO)Jenny Horsfield(CBO)Stuart McIntosh(CMO)David Sutherland(VP Finance & Controller)
Co-investorsARCH Venture PartnersB Capital GroupB4 CapitalCambridge Innovation Capital
Cerevance is a clinical-stage drug discovery and development company developing non-dopaminergic, orally-delivered therapies for brain and central nervous system disorders, including Parkinson's disease, schizophrenia, Alzheimer's disease, and ALS.
BiotechDeep TechHealthtech
Craig Thompson(Chief Executive Officer)Sagar Vaidya(Chief Medical Officer)Carrie Ann Cook(Chief Business Officer)
Co-investorsForesite CapitalGV (Google Ventures)Dementia Discovery FundSV Life SciencesDementia DiscoverySV Health Investors+2 more
HealthtechSanta Rosa, US
James Eadie(Director)Tony Fields(Executive Officer)Fred Khosravi(Director)Henry A. Plain(Director)Leo Nelson Hopkins(Director)
BoardAzin Parhizgar(Executive Officer, Director)
Co-investors415 Capital
CoolSculpting offers FDA-cleared body-contouring procedures that use controlled cooling to reduce visible fat bulges in areas such as the chin, abdomen, thighs, and flanks, along with the CoolTone device for muscle strengthening and toning.
HealthtechMedical DevicesWellness & Fitness
Co-investorsAisling Capital
Crystalys Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies for gout, a chronic metabolic disease caused by elevated uric acid.
BiotechHealthtechMedical DevicesSan Diego, US
James Mackay(President & Chief Executive Officer)inNihar Bhakta(Chief Medical Officer)inAshwin Ram(Chief Operating Officer)inDeAnne Reid(Chief Administrative Officer)in
Co-investorsCatalys PacificNovo HoldingsAN Venture PartnersFrazier Life SciencesLongwood Fund
Curie.Bio is a biotech venture firm pairing seed capital with in-house drug discovery support for therapeutics founders.
Zach Weinberg(Founder)in
Co-investorsAlleyCorpARCH Venture PartnersDNA CapitalF-Prime CapitalGV (Google Ventures)Shine Capital+1 more
Cyteir is a clinical-stage oncology company developing CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters.
BiotechHealthtechCambridge, US
Kevin Mills(Executive Officer, Director)Ronald Goldstein(Executive Officer)Donald Corcoran(Executive Officer, Director)Markus Renschler(Director)
BoardTimothy Romberger(Director)Barry Mills(Director)
Co-investorsDroia VenturesOUP (Osage University Partners)
Earlens makes a hearing aid that vibrates the eardrum directly rather than using speakers to amplify sound, allowing amplification across a broad audible frequency range including higher frequencies for speech understanding.
HardwareHealthtechMedical DevicesMenlo Park, US
Rodney Perkins, M.D.(Director)William M. Facteau(Executive Officer, Director)Bernard Shay(Executive Officer)Phil Lyons(Executive Officer)Brent Edwards(Executive Officer)Greg Koskowich(Executive Officer)
Co-investorsAisling CapitalNew Enterprise Associates (NEA)Windham Capital PartnersSightLine Partners
EndoGastric Solutions offers the Transoral Incisionless Fundoplication (TIF 2.0) procedure and the EsophyX device used to treat GERD, along with reimbursement and technical/administrative support (TAP program) for medical practices.
BiotechHealthtechMedical DevicesSan Mateo, US
Philip Macdonald(Executive Officer)Louis Baldino(Executive Officer, Director)Lilip Lau(Executive Officer)Josh DeFonzo(Executive Officer)
BoardMichael Carusi(Director)inArda Minocherhomjee(Director)
Co-investorsAccelmed PartnersCanaan PartnersEvidity Health CapitalVCFA GroupDe Novo VenturesFOUNDATION MEDICAL PARTNERS+1 more
FIRE1 develops NORM, an implantable sensor placed in the inferior vena cava to directly measure fluid volume in heart failure patients, paired with a self-management platform to help patients engage with their own care.
Digital HealthHardwareMedical DevicesDublin, IE
Co-investorsAndera PartnersLongitude CapitalNew Enterprise Associates (NEA)Vensana Capital
BiotechSouth San Francisco, US
Lewis T. Williams(Executive Officer, Director)W. Michael Kavanaugh, M.D.(Executive Officer)Julie Hambleton, M.D.(Executive Officer)Francis W. Sarena(Executive Officer)Aron M. Knickerbocker(Executive Officer, Director)Marc L. Belsky(Executive Officer)
Co-investorsDBL Partners
Co-investorsDBL Partners
Flex Pharma provides accessible generic vasodilator medications, including PDE5 inhibitors, to U.S. patients at lower costs than brand-name alternatives.
BiotechDigital HealthHealthtechMedical Devices
Dr. Rod MacKinnon(Founder)
Co-investorsBessemer Venture PartnersEcoR1 CapitalLongwood Fund
HealthtechMenlo Park, US
Eugene de Juan, Jr., M.D.(Director)K. Angela Macfarlane(Executive Officer, Director)John F. Maroney(Executive Officer, Director)
BoardRobert C. Bellas, Jr.(Director)Hanson S. Gifford III(Executive Officer, Director)Jim Glasheen(Director)
Co-investorsH.I.G. CapitalH.I.G. HealthBridge PartnersVersant Ventures
BiotechCambridge, US
James McLaughlin(Executive Officer, Director)
BoardJean George(Director)Jason Rhodes(Director)Carl Gordon(Director)in
Co-investorsAtlas VentureOrbiMed
BiotechCambridge, US
Magdalene Moran, Ph.D.(Executive Officer)Bert Chenard, Ph.D.(Executive Officer)Russell Herndon(Executive Officer, Director)Tom Burke(Executive Officer)
BoardVincent Miles(Director)Jean George(Director)
Co-investorsNew Enterprise Associates (NEA)
Co-investorsExSight Ventures
Day One (part of Servier) is a biopharmaceutical company developing targeted oncology medicines, with a focus on cancers affecting patients of all ages, including pediatric low-grade glioma (pLGG).
BiotechHealthtechCambridge, US
MICHAEL J. KAUFMAN(Executive Officer)DONALD BERGSTROM(Executive Officer)ANNA PROTOPAPAS(Executive Officer, Director)TIMOTHY LOWINGER(Executive Officer)EVA JACK(Executive Officer)WAYNE FOSTER(Executive Officer)
Co-investorsBain Capital Life SciencesF-Prime CapitalNew Enterprise Associates (NEA)Nextech InvestPfizer Venture InvestmentsRho Ventures
Terumo Neuro develops medical devices for treating and preventing hemorrhagic and ischemic stroke, including solutions for aneurysms, neurovascular malformations, carotid artery disease, aspiration catheters, stentrievers, and stents.
Medical Devices
HealthtechFremont, US
Anton Clifford(Executive Officer)James Leech(Executive Officer)Christopher Gleason(Executive Officer)Kevin K. Sidow(Executive Officer, Director)
BoardJoshua Makower(Director)Shahzad Malik(Director)in
Co-investorsNew Enterprise Associates (NEA)Runway Growth CapitalAdvent Life SciencesGBS Venture Partners Ltd.Gilde HealthcareVertex Ventures HC
Harnesses cutting-edge technologies to design exquisitely selective small molecule therapeutics.
Co-investorsAccess BiotechnologyBain Capital Life SciencesPfizer Venture InvestmentsRA CapitalSV Health Investors
Co-investorsPappas Capital
Pharmaceutical company acquired by Alexion in 2020.
Co-investorsBluebird VenturesProspect Venture Partners
Developed cancer therapeutics targeting the proteasome; acquired by Onyx Pharmaceuticals for up to $851M.
Co-investorsLatterell Venture PartnersUS Venture Partners
Prover Medical develops the ProVee System, a retrievable nitinol stent and delivery device that opens the obstructed prostatic urethra to relieve lower urinary tract symptoms caused by benign prostatic hyperplasia (BPH) without cutting, heating, or removing prostate tissue.
HardwareHealthtechMedical Devices
Dr Conor Harkin(Founder)inRíona Ní Ghriallais(Founder)in
Co-investorsOrbiMedIreland Strategic Investment FundMVM Life Science Partners
BiotechCambridge, US
Douglas A. Treco(Executive Officer, Director)Kerry Black(Executive Officer)
BoardEdward Mathers(Director)Rajeev Shah(Director)inPeter Bisgaard(Director)Jason Lettman(Director)
Co-investorsNew Enterprise Associates (NEA)RA Capital
Relievant offers the Intracept Procedure, a minimally invasive, FDA-cleared medical intervention designed to relieve chronic low back pain caused by vertebrogenic pain.
Medical DevicesRedwood City, US
Alex DiNello(Executive Officer, Director)
BoardRichard Mott(Director)Justin Klein(Director)inBrent Ahrens(Director)inJason Lettman(Director)John Ryan(Director)
Co-investorsCanaan PartnersEmergent Medical Partners, LLPNew Enterprise Associates (NEA)Vensana Capital
SetPoint Medical develops an FDA-approved implantable neurostimulation device that stimulates the vagus nerve to reduce inflammation, offering a device-based treatment for adults with moderate-to-severe rheumatoid arthritis who have not responded to biologic or targeted synthetic drugs.
BiotechHealthtechMedical DevicesValencia, US
Murthy Simhambhatla(CEO)David Chernoff(Chief Medical Officer (MD))Yaakov Levine(PhD)Rohan Seth(Executive Officer)
BoardBlake Wu(Director)Juan-Pablo Mas(Director)
Co-investorsAlly Bridge GroupNew Enterprise Associates (NEA)Norwest Venture PartnersTopspin PartnersCatalio Capital Management, LPCitta Capital+4 more
Tagworks Pharmaceuticals develops cancer therapies using its Click-to-Release platform, a chemical reaction that activates antibody-drug conjugates (ADCs), masked immunomodulators, and other prodrugs on-target while deactivating radioimmunotherapies off-target.
BiotechHealthtechMedical DevicesNijmegen, NL
Co-investorsBifNew Enterprise Associates (NEA)Novartis Venture FundYsios CapitalGilde HealthcareOost NL
Tallac Therapeutics is a biopharmaceutical company developing oligonucleotide-based antibody drug conjugates (ADCs) to treat cancer, including its Toll-like Receptor Agonist Antibody Conjugates (TRAAC) that deliver a TLR9 agonist to activate immune responses within the tumor microenvironment.
BiotechHealthtechBurlingame, US
Co-investorsMRL Ventures FundvenBio PartnersMatrix Partners ChinavenBio Global Strategic
The Foundry is a medical device incubator that identifies unmet clinical needs and builds companies around new technologies to address them, working with physician collaborators to develop products from concept to market.
BiotechDeep TechHealthtechMedical Devices
Co-investorsNew Enterprise Associates (NEA)
Tizona Therapeutics is a biotechnology company developing first-in-class immuno-oncology therapeutics, including its lead clinical-stage asset TTX-080, aimed at changing cancer progression and relapse.
AI & Machine LearningBiotechHealthtech
Vijay K. Kuchroo(Scientific Co-Founder & Advisory Board Member)Drew Pardoll(Scientific Co-Founder & Advisory Board Member)Dario Vignali(Scientific Co-Founder & Advisory Board Member)Jedd Wolchok(Scientific Co-Founder & Advisory Board Member)Christine O'Brien(Chief Executive Officer & Board Member)Courtney Beers(Chief Scientific Officer)
Co-investorsCanaan PartnersMPM BioImpactAbingworthGilead SciencesAstellas Venture Management LLC
Trishula Therapeutics is a clinical-stage biopharmaceutical company developing TTX-030, a first-in-class anti-CD39 antibody for advanced cancers.
BiotechHealthtech
Anil Singhal(President and CEO)Siddhartha Mitra(Chief Medical Officer)
Co-investorsCanaan PartnersMPM BioImpactAstellas Venture Management LLC
San Diego biotech founded in 2019 developing oral anti-inflammatory small molecules targeting RNA binding proteins.
Co-investorsARCH Venture PartnersMedical Excellence Capital
An R&D-driven biopharmaceutical company that uses AI to develop breakthrough medicines and vaccines focused on immune system disorders across five therapeutic areas.
AI & Machine LearningBiotechMedical DevicesCambridge, US
Ivana Magovcevic-Liebisch(Executive Officer, Director)Christopher Verni(Executive Officer)Mary Thistle(Director)Evan Thackaberry(Executive Officer)Suzanne Bruhn(Director)Gerhard Koenig(Director)
Co-investorsAtlas VentureVida VenturesHatteras Venture PartnersLongwood Fund
Nimbus Therapeutics designs and develops small molecule medicines using computational drug design and translational medicine.
BiotechDeep Tech
Co-investorsAtlas VenturePfizer Venture Investments
Co-investorsVensana Capital
Co-investorsWindham Capital Partners
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Exits · 6
IPOs and acquisitions across the tracked portfolioShoulder InnovationsNYSE: SIAlx OncologyNASDAQ: ALXOVerastemNASDAQ: VSTMGynesonicsacq. by HologicPortola Pharmaceuticalsacq. by AlexionProteolixacq. by Onyx Pharmaceuticals
Portfolio news
latest coverage across their companiesAlx Oncology · investing.com · Aug 18, 2026
Amber Therapeutics · foodsommelier.com · Jul 24, 2026
Apreo Health · funderintel.com · Jul 16, 2026
Verastem · insidermonkey.com · Jul 3, 2026
Twelve · startupsunion.com · Jul 2, 2026
Shoulder Innovations · investing.com · Jun 29, 2026
Mersana · ad-hoc-news.de · May 16, 2026
Reprieve Cardiovascular · massdevice.com · May 7, 2026
Frequently asked questions
- How many investments has Lightstone Ventures made?
- Lightstone Ventures has 77 tracked investments, 3 of which have exited via acquisition or IPO, including 3 dated in the last 24 months.
- What stage does Lightstone Ventures invest at?
- Lightstone Ventures invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does Lightstone Ventures focus on?
- Lightstone Ventures focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Lightstone Ventures located?
- Lightstone Ventures is headquartered in Portola Valley, US.
- Does Lightstone Ventures lead rounds?
- Yes, Lightstone Ventures leads investment rounds.
- Who does Lightstone Ventures co-invest with?
- Lightstone Ventures most often shares deals with New Enterprise Associates (NEA), Canaan Partners, Foresite Capital, among 128 tracked co-investors.
Co-investors · 19
New Enterprise Associates (NEA) is a venture capital firm that invests in and provides long-term support to founders building new companies.
Canaan Partners is a venture capital firm with over 30 years of history, backing companies across technology and healthcare sectors through close, hands-on partnerships with founders.
F-Prime Capital is an early-stage-focused investment firm backing companies across life sciences, technology, healthtech and services, and crypto.
Arboretum Ventures is a Midwest-based healthcare venture capital firm that invests in early-stage healthcare startups across medical devices, life science tools and diagnostics, tech-enabled care delivery, and pharma adjacencies.
SV Health Investors is a healthcare-focused investment firm that invests across multiple stages, geographies and healthcare sectors.
Venrock is a venture capital firm investing across technology and healthcare, backing companies in fintech, developer infrastructure, life sciences, therapeutics, semiconductors, and consumer products.
JAZZ Venture Partners is a venture capital firm investing in companies at the intersection of technology, neuroscience, and human performance, spanning digital health, biosciences, and AI.
The Novartis Venture Fund invests in innovative life science companies, focusing on biotechnology and biopharmaceuticals at various stages of growth, aiming to drive patient benefit and generate returns.
Samsara BioCapital is an investment firm backing the development of transformative therapeutics for patients, bringing together scientists, physicians, drug developers, and business leaders to support next-generation therapeutic breakthroughs.
Santé is a healthcare-focused investment firm that manages over $1 billion across venture and public-market strategies. Through Santé Ventures it backs private healthcare startups, and through Santé Capital it runs a liquid hedge fund strategy using proprietary data-science software.
Sofinnova Partners is a life sciences venture capital firm investing across the value chain from seed to later stage, with a focus on healthcare and sustainability. It backs companies in biopharma, medtech, digital medicine, agriculture and industrial processes.
SR One is a biotechnology-focused venture capital firm that partners with founders to develop innovative science into new medicines.
▶7 more co-investors
Johnson & Johnson Innovation – JJDCThe Column GroupMorgenthalerOptum VenturesRoche Venture FundNew Leaf Venture PartnersClarus Ventures
Firms observed investing alongside Lightstone Ventures, from public investor directories. Shared companies are the overlap with Lightstone Ventures's recorded portfolio.
Similar investors
.jpeg){kind=logo}
B Capital is a global investment firm backing early to late-stage technology innovators across technology, healthcare, and energy & resilience sectors.
DCVC (Data Collective) is a deep tech venture capital firm that backs entrepreneurs using computational approaches to solve large-scale real-world problems across many industries.
Khosla Ventures is a venture capital firm that invests in early-stage companies focused on technology, mobile, and clean energy sectors, including biotechnology applications. The firm provides capital and strategic support to entrepreneurs developing breakthrough technologies across multiple markets.
Pontifax is an investment firm focused on life sciences and healthcare technologies, backing companies across all development stages from early research to clinical-stage growth.
Accelmed Partners is a healthcare technology investment firm that applies a private equity approach to a sector traditionally served by venture and early-stage growth investors, focusing on tools & diagnostics, digital health, and tech-enabled services.